Pharma packaging design doesn't start with a mood board – it starts with the FDA labeling rule, the USP <1> look-alike/sound-alike check, and whatever tamper-evidence or child-resistant standard applies to your dosage form. The companies that stand out on shelf and reduce medication errors are the ones who treat those constraints as the brief, not the obstacle to it.
The Problem
Regulatory review kills packaging projects before they ship
Most packaging redesigns for pharma products die in regulatory review, not in creative review. A label change that looks like a small color or layout shift can trigger a new FDA submission, a labeling supplement, or a full USP <1> risk-of-confusion re-check against every other product in your portfolio. Teams that bring in a designer before they've mapped the regulatory pathway waste months on concepts that were never approvable.
Look-alike, sound-alike errors are a patient safety liability, not a design footnote
USP <1> exists because look-alike packaging causes real dispensing errors – a nurse or pharmacist grabs the wrong vial because two products in the same class share color, font, and layout. If your packaging design process doesn't include a formal LASA (look-alike, sound-alike) comparison against your own line and your competitors', you are shipping a design that could contribute to a medication error. That's a recall risk, not just a brand risk.
Child-resistant and tamper-evident requirements get bolted on instead of designed in
Packaging teams frequently design the primary structure first and retrofit CR closures or tamper bands afterward, which produces packaging that's technically compliant but painful for the elderly or dexterity-impaired patients who make up a large share of chronic therapy users. Failed usability testing at this stage means redoing tooling, not just artwork – a far more expensive fix than designing for both compliance and usability from day one.
Device and combination-product packaging adds a second regulatory system on top of the first
If your product includes an autoinjector, inhaler, or diagnostic component, your packaging now has to satisfy ISO 15378 and device-specific GMP requirements alongside standard drug labeling rules. Teams that treat this as one packaging project instead of two overlapping compliance systems end up with kit packaging that fails either the pharma review or the device review, and sometimes both.
How We Help
Our initial assessment starts with your regulatory pathway, not your brand guidelines. We review your product's classification, dosage form, and any prior FDA correspondence to establish what's actually changeable in your packaging without triggering a new submission, and what requires regulatory sign-off before a single concept gets drawn. This determines the design scope before it determines the design direction.
Strategy development builds the packaging system around the constraints that are fixed – required labeling elements, CR closure type, tamper-evidence method, USP <1> differentiation requirements – and finds the differentiation space that remains. For commercial pharma, that space is usually color coding by strength, typographic hierarchy that speeds correct dispensing, and structural choices that make your SKU physically distinct from look-alike competitors on the same shelf. For patient-facing device and combination-product kits, it extends to unboxing sequence and usability of the CR mechanism itself.
Execution runs the design and the regulatory review in parallel instead of sequentially, which is where most packaging timelines get shortened. We build comps that your regulatory and quality teams can review alongside the design team, so labeling copy, required statements, and LASA differentiation get validated before we're deep into production art. For kit and device packaging, we run structural prototypes through usability testing with the patient population your therapy actually serves – not a generalized consumer panel.
Measurement for pharma packaging tracks dispensing accuracy and patient usability, not just shelf appeal. We track pharmacist and nurse feedback on differentiation from look-alike products where that data is available, patient-reported ease of use for CR and device packaging, and time-to-approval on the regulatory submission itself. A packaging redesign that looks better but takes eight extra months to clear FDA review isn't a win.
What we deliver
- Regulatory pathway map – what triggers a new submission vs. what's changeable under your existing approval
- LASA differentiation audit – structural and visual comparison against look-alike, sound-alike products in your class
- Packaging system design – primary and secondary packaging built around required labeling, CR closure, and tamper-evidence constraints
- Patient usability testing plan – for CR closures, autoinjector kits, and combination-product packaging with the actual patient population
In pharma, the packaging that wins isn't the boldest one – it's the one that gets a patient to the correct dose without a second look, and gets through FDA review without a second submission. Differentiation lives inside that constraint, not outside it.
Our Methodology
Our 90-day packaging design sprint for biotech and pharma starts with the regulatory and quality teams, not the creative brief. Phase one maps the labeling requirements, USP <1> obligations, and CR/tamper-evidence standards that apply to your specific dosage form and therapeutic class, and identifies whether your planned changes fall inside your current approval or require a new submission.
Phase two develops the packaging system in parallel with regulatory review. We design primary and secondary packaging structures, run LASA comparisons against competitor and internal SKUs, and build the labeling hierarchy that helps a pharmacist or patient identify the right product and dose quickly. For device and combination products, this phase runs structural prototypes through the same usability testing FDA reviewers will expect to see documented.
Phase three implements the approved packaging across production – working with your printer and converter on color-matching, tooling, and CR closure validation – and closes the loop with post-launch usability feedback where it's available. Unlike a design agency that hands off finished art and exits, we stay engaged through the regulatory submission and first production run, because that's where most pharma packaging projects actually stall.
How We Work
Initial packaging engagements for biotech and pharma companies run 3-5 months, longer than a typical consumer packaging project because regulatory review sets the pace, not creative iteration. The first 30 days are regulatory and constraint mapping – we work with your regulatory affairs and quality teams to define exactly what's fixed and what's open before any design work starts.
Days 31-75 are design and parallel regulatory review. We produce comps and structural prototypes that your regulatory team reviews alongside us, so labeling language, LASA differentiation, and CR/tamper compliance get validated early rather than after full production art is built. For device and combination-product kits, this phase includes usability testing with real patients or caregivers from your therapy area.
The final phase moves into production – color matching, tooling for structural packaging, and CR closure validation with your converter or contract packager. We stay through the first production run and any post-market usability feedback collection.
Weekly working sessions with your regulatory, quality, and marketing stakeholders keep design and compliance moving together instead of in sequence. Monthly reviews track submission status and usability testing results against the original constraint map.
- Faster regulatory clearance – fewer review cycles because labeling and LASA differentiation were validated during design, not after
- Reduced dispensing-error risk – clearer differentiation from look-alike, sound-alike products in the same class
- Improved patient usability – CR closures and device kits tested with the actual patient population before production
- Shelf and formulary differentiation – packaging that reads as distinct without stepping outside required labeling elements
If your biotech & pharma company needs packaging design leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does packaging design cost for a pharma product?
Most engagements run $60K-$180K depending on whether the project is a labeling and secondary-packaging redesign or a full primary packaging and device-kit build with usability testing. Combination-product and autoinjector kit packaging sits at the higher end because it requires structural prototyping and patient usability studies, not just artwork. We scope cost after reviewing your current regulatory approval and what's actually open to change.
Will a packaging redesign trigger a new FDA submission?
It depends on what changes. Labeling copy, color, and layout changes to an approved product can trigger a labeling supplement or, in some cases, a full resubmission – which is why we map your regulatory pathway before any design work starts. Structural changes to primary packaging, CR closures, or device components almost always require regulatory review. We work with your regulatory affairs team from day one so the design scope matches what's actually approvable on your timeline.
How do you handle USP <1> look-alike, sound-alike requirements?
We run a formal LASA comparison against products in your own line and known competitors in the same therapeutic class before finalizing any design direction. That comparison looks at color, typography, layout, and container shape – the elements a pharmacist or nurse scans under time pressure. The goal is differentiation that's documented and defensible in your regulatory submission, not just a design team's subjective judgment that two packages look different enough.
Can you design packaging for combination products and device kits, or just commercial pharma cartons?
Both. Commercial carton and label work follows standard FDA labeling rules. Device and combination-product kit packaging – autoinjectors, inhalers, diagnostic kits – adds ISO 15378 and device GMP requirements on top, plus patient usability testing that FDA reviewers expect to see documented. We run these as one coordinated project rather than treating the drug and device sides as separate workstreams that get reconciled at the end.
What makes Winston Francois different from a pharma packaging agency?
Most packaging agencies either know regulatory constraint and produce safe, forgettable design, or know design and treat regulatory review as someone else's problem to solve after the fact. We run design and regulatory review in parallel from the start, which is what actually shortens the timeline to approval. We're operators who think about dispensing accuracy and patient usability as design requirements, not compliance checkboxes to clear after the creative is locked.
What type of biotech or pharma company is the right fit for this service?
Commercial-stage companies launching a new SKU, companies facing a USP <1> or LASA finding from a regulatory review, and any team bringing a combination product or device kit to market for the first time. If your current packaging process treats design and regulatory as sequential handoffs instead of a coordinated workstream, that's usually the first sign you need this. The first step is a review of your current packaging against its regulatory approval to find what's actually open to change.
